Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
Contineum Therapeutics (NASDAQ: CTNM), a clinical stage biopharmaceutical company developing oral small molecule therapies for neuroscience, inflammation and immunology conditions, has announced its participation in the 7th Annual Evercore HealthCONx Conference. The company's management will engage in a fireside chat on December 4, 2024, at 11:15 a.m. ET in Miami. The event will be accessible via audio webcast through Contineum's website's Investors section, with a replay option available.
Contineum Therapeutics (NASDAQ: CTNM), un'azienda biofarmaceutica in fase clinica che sviluppa terapie orali a base di piccole molecole per condizioni di neuroscienze, infiammazione e immunologia, ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore HealthCONx. La direzione dell'azienda parteciperà a una chiacchierata informale il 4 dicembre 2024 alle 11:15 EST a Miami. L'evento sarà accessibile tramite audio webcast nella sezione Investitori del sito web di Contineum, con possibilità di riproduzione successiva.
Contineum Therapeutics (NASDAQ: CTNM), una empresa biofarmacéutica en fase clínica que desarrolla terapias orales con pequeñas moléculas para condiciones de neurología, inflamación e inmunología, ha anunciado su participación en la 7ª Conferencia Anual Evercore HealthCONx. La dirección de la empresa participará en una charla informal el 4 de diciembre de 2024 a las 11:15 a.m. ET en Miami. El evento será accesible a través de un webcast de audio en la sección de Inversionistas del sitio web de Contineum, con una opción de repetición disponible.
Contineum Therapeutics (NASDAQ: CTNM)는 신경과학, 염증 및 면역학 조건을 위한 경구용 소분자 치료제를 개발하는 임상 단계의 생물 제약 회사로, 제7회 연례 Evercore HealthCONx 컨퍼런스에 참석할 것이라고 발표했습니다. 회사의 경영진은 2024년 12월 4일 오전 11시 15분 ET에 마이애미에서 화기애애한 대화에 참여할 예정입니다. 해당 이벤트는 Contineum 웹사이트의 투자자 섹션을 통해 오디오 웹캐스트로 접근 가능하며, 재생 옵션도 제공됩니다.
Contineum Therapeutics (NASDAQ: CTNM), une entreprise biopharmaceutique en phase clinique développant des thérapies orales à base de petites molécules pour des conditions en neurosciences, inflammation et immunologie, a annoncé sa participation à la 7e Conférence Annuelle Evercore HealthCONx. La direction de l'entreprise s'engagera dans une discussion informelle le 4 décembre 2024 à 11h15 ET à Miami. L'événement sera accessible via un audio webcast dans la section Investisseurs du site internet de Contineum, avec une option de rediffusion disponible.
Contineum Therapeutics (NASDAQ: CTNM), ein biopharmazeutisches Unternehmen in klinischer Phase, das orale kleine Molekültherapien für neurologische, entzündliche und immunologische Erkrankungen entwickelt, hat seine Teilnahme an der 7. Jahrestagung Evercore HealthCONx bekannt gegeben. Die Unternehmensleitung wird am 4. Dezember 2024 um 11:15 Uhr ET in Miami an einem Fireside-Chat teilnehmen. Die Veranstaltung wird über einen Audio-Webcast im Investments-Bereich von Contineums Website zugänglich sein, mit einer verfügbaren Wiedergabemöglichkeit.
- None.
- None.
An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of disease. Contineum has a pipeline of internally-developed programs to address multiple NI&I disorders. Contineum has two drug candidates in clinical trials, PIPE-791, an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307, a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis. PIPE-307 is being developed pursuant to a global license and development agreement between Contineum and Janssen Pharmaceutica NV, a Johnson & Johnson company, who has also announced plans to initiate a Phase 2 trial of PIPE-307 in depression in 2024. For more information, please visit www.contineum-tx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125236974/en/
Steve Kunszabo
Contineum Therapeutics
Senior Director, Investor Relations & Corporate Communications
858-649-1158
skunszabo@contineum-tx.com
Source: Contineum Therapeutics, Inc.
FAQ
When is Contineum Therapeutics (CTNM) presenting at the Evercore HealthCONx Conference 2024?
How can investors access Contineum Therapeutics' (CTNM) presentation at the Evercore Conference?
What type of therapies is Contineum Therapeutics (CTNM) developing?
Which conference is Contineum Therapeutics (CTNM) attending in December 2024?
